Genetic Tangible Asset Value from 2010 to 2024
| GENE Stock | USD 3.16 0.01 0.32% |
Tangible Asset Value | First Reported 2010-12-31 | Previous Quarter 10.6 M | Current Value 10.5 M | Quarterly Volatility 556 K |
Check Genetic Technologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Genetic main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Interest Expense of 32.2 K or Total Revenue of 5.3 M, as well as many exotic indicators such as Price To Sales Ratio of 62.62, Dividend Yield of 0.0 or PTB Ratio of 39.42. Genetic financial statements analysis is a perfect complement when working with Genetic Technologies Valuation or Volatility modules.
Genetic | Tangible Asset Value |
Latest Genetic Technologies' Tangible Asset Value Growth Pattern
Below is the plot of the Tangible Asset Value of Genetic Technologies over the last few years. It is the total value of a company's physical, tangible assets, excluding intangible assets like patents and trademarks. Genetic Technologies' Tangible Asset Value historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Genetic Technologies' overall financial position and show how it may be relating to other accounts over time.
| Tangible Asset Value | 10 Years Trend |
|
Tangible Asset Value |
| Timeline |
Genetic Tangible Asset Value Regression Statistics
| Arithmetic Mean | 11,508,537 | |
| Geometric Mean | 11,495,341 | |
| Coefficient Of Variation | 4.83 | |
| Mean Deviation | 425,323 | |
| Median | 11,774,364 | |
| Standard Deviation | 555,976 | |
| Sample Variance | 309.1B | |
| Range | 1.6M | |
| R-Value | (0.14) | |
| Mean Square Error | 326.6B | |
| R-Squared | 0.02 | |
| Significance | 0.63 | |
| Slope | (17,077) | |
| Total Sum of Squares | 4.3T |
Genetic Tangible Asset Value History
About Genetic Technologies Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Genetic Technologies income statement, its balance sheet, and the statement of cash flows. Genetic Technologies investors use historical funamental indicators, such as Genetic Technologies's Tangible Asset Value, to determine how well the company is positioned to perform in the future. Although Genetic Technologies investors may use each financial statement separately, they are all related. The changes in Genetic Technologies's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Genetic Technologies's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Genetic Technologies Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Genetic Technologies. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Tangible Asset Value | 10.6 M | 10.5 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Genetic Technologies Correlation against competitors. For information on how to trade Genetic Stock refer to our How to Trade Genetic Stock guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Complementary Tools for Genetic Stock analysis
When running Genetic Technologies' price analysis, check to measure Genetic Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genetic Technologies is operating at the current time. Most of Genetic Technologies' value examination focuses on studying past and present price action to predict the probability of Genetic Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genetic Technologies' price. Additionally, you may evaluate how the addition of Genetic Technologies to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |
Is Genetic Technologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genetic Technologies. If investors know Genetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genetic Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 2.73 | Quarterly Revenue Growth (0.02) | Return On Assets (0.53) | Return On Equity (1.60) |
The market value of Genetic Technologies is measured differently than its book value, which is the value of Genetic that is recorded on the company's balance sheet. Investors also form their own opinion of Genetic Technologies' value that differs from its market value or its book value, called intrinsic value, which is Genetic Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genetic Technologies' market value can be influenced by many factors that don't directly affect Genetic Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genetic Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Genetic Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genetic Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.